AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35821349 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) protocol
Number of subjects: 0
Study 35821380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks
Number of subjects: 269
Study 35821380 — intervention group
Group type: COMPARATOR
Intervention: Non-injection-intensive patients
Number of subjects: 269
Study 35821806 — intervention group
Group type: EXPERIMENTAL
Intervention: Uthever (NMN Supplement)
Number of subjects: 0
Study 35821806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35821820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program
Number of subjects: 0
Study 35821820 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35821844 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at low dose (2.4 g/day) for 2 weeks
Number of subjects: 114
Study 35821844 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at medium dose (4.8 g/day) for 2 weeks
Number of subjects: 114
Study 35821844 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine and N-Acetylcysteine supplementation (GlyNAC) at high dose (7.2 g/day) for 2 weeks
Number of subjects: 114
Study 35822301 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (CRP, IL-6, procalcitonin [PCT])
Number of subjects: 215
Study 35822301 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (CRP, IL-6, PCT)
Number of subjects: 215
Study 35822301 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP, IL-6, PCT levels
Number of subjects: 215
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 2550
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP refill at 1 month
Number of subjects: 2550
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP persistence at 6 months
Number of subjects: 2550
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP restart after gap
Number of subjects: 2550
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: Average PrEP dosing
Number of subjects: 2550
Study 35822945 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seroconversions
Number of subjects: 2550
Study 35829629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy
Number of subjects: 1
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 620
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic events
Number of subjects: 620
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bleeding and thrombosis
Number of subjects: 620
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 620
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation duration before ECMO ≥ 7 days
Number of subjects: 620
Study 35829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ECMO support
Number of subjects: 620
Study 35829748 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nanobody without a hexahistidine (His)
Number of subjects: 0
Study 35829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R1)
Number of subjects: 419
Study 35829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R2)
Number of subjects: 419
Study 35829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R3)
Number of subjects: 419
Study 35829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with intensive chemotherapy (group R4)
Number of subjects: 419
Study 35829780 — intervention group
Group type: COMPARATOR
Intervention: Historical data (control group)
Number of subjects: 419
Study 35829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (toxicities)
Number of subjects: 419
Study 35829947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 17
Study 35830223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-km outdoor cardio trekking test trail
Number of subjects: 144
Study 35830223 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-km hiking trails
Number of subjects: 144
Study 35830223 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill test in the laboratory
Number of subjects: 144
Study 35830239 — intervention group
Group type: EXPERIMENTAL
Intervention: C3-Cloud collaborative computer platforms for patients and multidisciplinary team members
Number of subjects: 3
Study 35830245 — intervention group
Group type: EXPERIMENTAL
Intervention: Brothers Saving Brothers (BSB) motivational interviewing behavioral intervention
Number of subjects: 0
Study 35830245 — intervention group
Group type: EXPERIMENTAL
Intervention: Kings intervention (adapted BSB intervention)
Number of subjects: 0
Study 35830251 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led nutrition and exercise intervention over 12 weeks
Number of subjects: 20
Study 35830251 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led nutrition and exercise intervention
Number of subjects: 20
Study 35830343 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF core set for post-acute musculoskeletal conditions
Number of subjects: 84
Study 35830343 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive ICF Core Set for Subacute Musculoskeletal Conditions
Number of subjects: 84
Study 35830435 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical, ultrasonographic, biophysical and biochemical variables
Number of subjects: 429
Study 35830435 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected at 40 weeks
Number of subjects: 429
Study 35830474 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 805
Study 35830597 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 with diabetes
Number of subjects: 1000
Study 35830625 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Number of subjects: 20
Study 35830625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Supportive Oncology Care at Home)
Number of subjects: 20
Study 35830707 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trials (SBTs) without added pressure support
Number of subjects: 0
Study 35830707 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured approach including daily assessment of readiness to extubate
Number of subjects: 0
Study 35830707 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of elevated load and impaired respiratory muscle capacity
Number of subjects: 0
Study 35830841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin at 3.2 mg/m
Number of subjects: 31
Study 35830931 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 1 mg/kg/day, with 11 infusions per cycle of 28 days at a dose of 0.15 mg/kg per infusion.
Number of subjects: 21
Study 35830931 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) treatment
Number of subjects: 21
Study 35830959 — intervention group
Group type: EXPERIMENTAL
Intervention: Joy for All (JfA) devices (1 cat and 1 dog)
Number of subjects: 253
Study 35830959 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 253
Study 35831040 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation in NSTEMI patients
Number of subjects: 1506
Study 35831040 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation in UAP patients
Number of subjects: 1506
Study 35831040 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment in UAP patients
Number of subjects: 1506
Study 35831040 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI patients
Number of subjects: 1506
Study 35831040 — intervention group
Group type: EXPERIMENTAL
Intervention: UAP patients
Number of subjects: 1506
Study 35831043 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrip electrode array for continuous electrocorticography monitoring for seizures and CSDs.
Number of subjects: 0
Study 35831043 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural electrodes for continuous monitoring.
Number of subjects: 0
Study 35831051 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality assessment tool 'Spheres & Shield Maze Task' and speech analysis
Number of subjects: 300
Study 35831051 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of impulsivity (Barratt Impulsiveness Scale 11, Urgency, Premeditation, Perseverance, Sensation Seeking, Positive Urgency, Impulsive Behaviour Scale, Iowa Gambling Task, Continuous Performance Test, Stop signal Task, Go/no-go task)
Number of subjects: 300
Study 35831057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (specific intervention details not provided)
Number of subjects: 0
Study 35831701 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA International Registry for Behçet's disease patients
Number of subjects: 290
Study 35831783 — intervention group
Group type: EXPERIMENTAL
Intervention: MRd (Medication Reconciliation at discharge)
Number of subjects: 0
Study 35832045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation of masticatory function with fixed implant-supported dentures and nutrition education
Number of subjects: 0
Study 35832045 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35832177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg/day after initial dose escalation for up to 60 months
Number of subjects: 1300
Study 35832177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg/day
Number of subjects: 1300
Study 35832286 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hsCRP levels (>3 mg/l) in FM patients
Number of subjects: 70
Study 35832286 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hsCRP levels in FM patients
Number of subjects: 70
Study 35832286 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 35832351 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise program
Number of subjects: 60
Study 35832351 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise program
Number of subjects: 60
Study 35832414 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors and digital alerting systems
Number of subjects: 0
Study 35832414 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35832447 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg intravenously every 2 weeks plus apatinib 250 mg orally once daily
Number of subjects: 43
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 117
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors (personality traits, attachment type, traumatic life events)
Number of subjects: 117
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 117
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized anxiety
Number of subjects: 117
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety about the COVID-19 pandemic
Number of subjects: 117
Study 35832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 117
Study 35833019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Number of subjects: 0
Study 35833116 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab (IgG1 anti-PD-1 antibody)
Number of subjects: 0
Study 35833116 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab
Number of subjects: 0
Study 35833199 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with sham tDCS
Number of subjects: 0
Study 35833199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with active tDCS
Number of subjects: 0
Study 35833254 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-related socioeconomic insecurity
Number of subjects: 66
Study 35833254 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic conditions
Number of subjects: 66
Study 35833911 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency VNS
Number of subjects: 439
Study 35833911 — intervention group
Group type: COMPARATOR
Intervention: Low frequency VNS
Number of subjects: 439
Study 35833911 — intervention group
Group type: EXPERIMENTAL
Intervention: VNS stimulation
Number of subjects: 439
Study 35833913 — intervention group
Group type: COMPARATOR
Intervention: DL-3-n-butylphthalide (24 weeks treatment)
Number of subjects: 3384
Study 35833913 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (4 years treatment)
Number of subjects: 3384
Study 35833913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 3384
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (remnant-C)
Number of subjects: 10196
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit remnant-C variability (logSD)
Number of subjects: 10196
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit remnant-C variability (logARV)
Number of subjects: 10196
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline remnant-C (≥31 mg/dL)
Number of subjects: 10196
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline remnant-C in LDL-C subgroup (>100 mg/dL)
Number of subjects: 10196
Study 35834242 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline remnant-C in LDL-C subgroup (≤100 mg/dL)
Number of subjects: 10196
Study 35834315 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx improvement approach
Number of subjects: 43
Study 35834315 — intervention group
Group type: COMPARATOR
Intervention: Traditional product training model
Number of subjects: 43
Study 35834508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepectoral breast reconstruction (PBR)
Number of subjects: 81
Study 35834598 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant mFOLFOXIRI chemotherapy
Number of subjects: 106
Study 35834645 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial transcriptome analysis
Number of subjects: 0
Study 35834646 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35835008 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT)
Number of subjects: 0
Study 35835008 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of serum urate (SU)
Number of subjects: 0
Study 35835008 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum urate (SU) levels
Number of subjects: 0
Study 35835008 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent fluctuations in serum urate (SU) levels
Number of subjects: 0
Study 35835061 — intervention group
Group type: EXPERIMENTAL
Intervention: SOBI003 (3 mg/kg)
Number of subjects: 6
Study 35835061 — intervention group
Group type: EXPERIMENTAL
Intervention: SOBI003 (10 mg/kg)
Number of subjects: 6
Study 35835061 — intervention group
Group type: EXPERIMENTAL
Intervention: SOBI003 (up to 20 mg/kg during extension study)
Number of subjects: 6
Study 35835061 — intervention group
Group type: EXPERIMENTAL
Intervention: SOBI003 (all doses)
Number of subjects: 6
Study 35835137 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib 60 mg once daily (intermittent dosing)
Number of subjects: 97
Study 35835137 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib 120 mg once daily (intermittent dosing)
Number of subjects: 97
Study 35835137 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib 180 mg once daily (intermittent dosing)
Number of subjects: 97
Study 35835137 — intervention group
Group type: COMPARATOR
Intervention: Zandelisib (intermittent dosing)
Number of subjects: 97
Study 35835137 — intervention group
Group type: COMPARATOR
Intervention: Zandelisib (continuous dosing)
Number of subjects: 97
Study 35835137 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib (both dosing schedules)
Number of subjects: 97
Study 35835342 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CADx) module for differentiating between adenoma and nonadenoma in unmagnified white-light colonoscopy
Number of subjects: 162
Study 35835342 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted endoscopist predictions with electronic chromoendoscopy
Number of subjects: 162
Study 35835342 — intervention group
Group type: EXPERIMENTAL
Intervention: CADx output for resect-and-discard strategy
Number of subjects: 162
Study 35835342 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between CADx and histology-based surveillance intervals
Number of subjects: 162
Study 35835491 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI staging system parameters (hypotension, hypoperfusion, treatment intensity)
Number of subjects: 3455
Study 35835491 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure, lactate level, alanine transaminase level, systemic pH
Number of subjects: 3455
Study 35835491 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and maximum SCAI stages
Number of subjects: 3455
Study 35835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black individuals
Number of subjects: 436
Study 35835495 — intervention group
Group type: COMPARATOR
Intervention: Hispanic individuals
Number of subjects: 436
Study 35835523 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased visceral fat and total body fat
Number of subjects: 306
Study 35835523 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic factors
Number of subjects: 306
Study 35835523 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hand OA
Number of subjects: 306
Study 35835611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles
Number of subjects: 84
Study 35835615 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Database (GDB)
Number of subjects: 91000
Study 35835670 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 1430
Study 35835670 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 1430
Study 35835670 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1430
Study 35835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-dependent phagocytosis of ring-infected erythrocytes
Number of subjects: 0
Study 35835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-dependent phagocytosis of uninfected erythrocytes
Number of subjects: 0
Study 35835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface proteomic analysis revealing merozoite proteins (erythrocyte binding antigen-175 and -140)
Number of subjects: 0
Study 35835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition phagocytosis assays
Number of subjects: 0
Study 35835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting ring-stage parasites
Number of subjects: 0
Study 35836289 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Distress Questionnaire (PDQ)
Number of subjects: 114
Study 35836289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol measurements from maternal hair strands
Number of subjects: 114
Study 35836289 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated methylation regions (DMR) related to maternal stress measures PDQ and cortisol
Number of subjects: 114
Study 35837099 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 186
Study 35837200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated proton therapy with elective nodal irradiation (40.5 GyRBE in 18 fractions followed by 22.5 GyRBE boost); Oral capecitabine (1,000 mg twice daily) during treatment
Number of subjects: 15
Study 35837200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated proton therapy with elective nodal irradiation
Number of subjects: 15
Study 35837409 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan-DV vaccine
Number of subjects: 40
Study 35837483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV) during preoperative DC-EEG measurement
Number of subjects: 15
Study 35837483 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of Anesthesia (IOA)
Number of subjects: 15
Study 35838207 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitumor treatment (surgery, radiotherapy, chemotherapy)
Number of subjects: 0
Study 35838207 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug (AED) treatment (levetiracetam)
Number of subjects: 0
Study 35838207 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential add-on AEDs (lacosamide, perampanel, valproic acid)
Number of subjects: 0
Study 35838207 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines via nonoral administration routes
Number of subjects: 0
Study 35838424 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-era cohort
Number of subjects: 2
Study 35838424 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-era cohort
Number of subjects: 2
Study 35838761 — intervention group
Group type: EXPERIMENTAL
Intervention: myFAMI intervention (smartphone app with triggered nurse communication)
Number of subjects: 1800
Study 35838993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg 1% propofol (group P: n = 30)
Number of subjects: 113
Study 35838993 — intervention group
Group type: COMPARATOR
Intervention: No propofol administration (group C: n = 83)
Number of subjects: 113
Study 35839001 — intervention group
Group type: EXPERIMENTAL
Intervention: New dispatcher-assisted basic life support training program
Number of subjects: 10127
Study 35839001 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 districts without the new training program)
Number of subjects: 10127
Study 35839129 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0